Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial.Eric Van Cutsem, Axel Grothey, Marc Ychou et al.|Journal of Clinical Oncology|2013Cited by 24
Population Pharmacokinetics Analysis of Regorafenib and Its Active Metabolites From the Phase III Correct Study of Metastatic Colorectal CancerZuzana Jirakova Trnkova, Eric Van Cutsem, Axel Grothey et al.|Annals of Oncology|2013Cited by 7